East Mab

Executive Summary

East Mab is a private, China-based biotechnology company established in 2015, specializing in the discovery and development of therapeutic monoclonal antibodies for oncology and immunology. Leveraging hybridoma and phage display platforms, the company aims to create high-affinity antibody therapies addressing unmet medical needs. Currently in Phase 1 stage with no disclosed pipeline assets, East Mab operates with 50-200 employees and is headquartered in Suzhou. Given its early-stage focus on innovative antibody discovery, the company's value proposition hinges on advancing its preclinical candidates into clinical development. The lack of public data on specific programs, funding, or partnerships introduces significant uncertainty, typical for private biotechs at this stage. However, the growing demand for targeted therapies in China and the company's proprietary technology platforms provide a foundational basis for potential growth.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human Phase 1 trial for lead antibody candidate30% success
• Q2 2026IND filing or clearance for a novel oncology/immunology asset25% success
• TBDAnnouncement of strategic partnership or licensing deal with a larger pharma20% success